Nanohale AG (ETR:FYB) | Finanzwire

Basculer en Français

9529	Companies
187435	Keywords
119456	Articles
100182	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 11/17/2025 at 06:35, 28 days 10 hours ago

Formycon Reaches Milestone with FYB208 for Dupixent®

Biosimilars Formycon Chronic Inflammatory Diseases Dupilumab Technical Proof Of Similarity
PRESS RELEASE

published on 11/17/2025 at 06:30, 28 days 10 hours ago

Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio
Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio

Growth Biosimilar Formycon Dupixent FYB208
BRIEF

published on 11/13/2025 at 06:35, 1 month 2 days ago

Formycon AG Confirms 2025 Guidance Amid Pipeline and Partnership Progress

Financial Results Strategic Partnerships Formycon AG Biosimilars Market Expansion
PRESS RELEASE

published on 11/13/2025 at 06:30, 1 month 2 days ago

Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
Formycon AG publishes nine-month results, reaffirms 2025 guidance with strong pipeline progress and partnerships. Read about fiscal performance and strategic advancements

Formycon AG Partnerships Pipeline Progress Nine-month Results 2025 Guidance
BRIEF

published on 10/30/2025 at 06:35, 1 month 16 days ago

Formycon AG Schedules Conference Call for 2025 Results and Investor Engagement

Financial Results Conference Call Investor Conferences Formycon AG Biosimilars
PRESS RELEASE

published on 10/30/2025 at 06:30, 1 month 16 days ago

Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Formycon AG to discuss 2025 Nine-Month Results in Conference Call and participate in Investor Conferences. Company specializes in biosimilars for various disease areas

Financial Results Conference Call Investor Conferences Formycon AG Biosimilars
BRIEF

published on 10/21/2025 at 06:35, 1 month 25 days ago

Formycon Launches Europe’s First Ranibizumab Biosimilar in Pre-filled Syringe

Teva Pharmaceuticals Ranibizumab Biosimilar Pre-filled Syringe FYB201/Ranivisio® Formycon Launch
PRESS RELEASE

published on 10/21/2025 at 06:30, 1 month 25 days ago

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Formycon's FYB201/Ranivisio® is Europe's First Ranibizumab Biosimilar available in Pre-filled Syringe, offering improved handling, accuracy, and convenience for applicants. Teva to commercialize across Europe

Europe Biosimilar Formycon Teva Ranivisio
BRIEF

published on 10/16/2025 at 06:35, 1 month 30 days ago

Actor Pharmaceuticals and Megalabs Partner for FYB203 Commercialization

Formycon AG Eylea® Biosimilar Actor Pharmaceuticals Megalabs FYB203 Commercialization
PRESS RELEASE

published on 10/16/2025 at 06:30, 1 month 30 days ago

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Actor Pharmaceuticals and Megalabs to commercialize Formycon's Eylea biosimilar FYB203 in Australia and Latin America. Partnership agreements include upfront payments and royalties

Partnerships Commercialization Biosimilar Formycon Eylea

Accesswire

Published on 12/15/2025 at 16:35, 46 minutes ago

Stillwater Critical Minerals Announces Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$15 Million
Published on 12/15/2025 at 15:00, 2 hours 21 minutes ago

Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 2 hours 21 minutes ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 2 hours 51 minutes ago

Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix
Published on 12/15/2025 at 14:00, 3 hours 21 minutes ago

Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum

View all ACCESSWIRE

EQS Group

Published on 12/15/2025 at 17:15, 5 minutes ago

His Highness Sheikh Mansour bin Zayed Al Nahyan Launches "Al Khail Square" at Abu Dhabi Equestrian Club
Published on 12/15/2025 at 17:05, 15 minutes ago

Gensyn Launches $AI Token Sale on Sonar
Published on 12/15/2025 at 16:42, 38 minutes ago

EQS-Adhoc: Vitruvia Medical AG: successfull capital increase and strengthening of the financial structure
Published on 12/15/2025 at 16:08, 1 hour 13 minutes ago

Conversion of The Platform Group AG into a KGaA completed as planned
Published on 12/15/2025 at 15:50, 1 hour 30 minutes ago

Original-Research: Cabka N.V. (von First Berlin Equity Research GmbH): Kaufen

Les Echos

Published on 12/15/2025 at 11:50, 5 hours 30 minutes ago

Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025
Published on 12/12/2025 at 18:00, 2 days 23 hours ago

Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/12/2025 at 09:15, 3 days 8 hours ago

CHANGE IN THE SHARE CAPITAL
Published on 12/11/2025 at 19:23, 3 days 21 hours ago

Eiffage is joining the CAC 40 index
Published on 12/11/2025 at 08:30, 4 days 8 hours ago

Edenred and Daimler Truck join forces to accelerate the rollout of charging infrastructure for electric trucks in Europe

View all LES ECHOS COMFI WIRE